Moderna, Inc. (LON:0A45)

Market Cap	11.60B -16.6%
Revenue (ttm)	1.66B -56.1%
Net Income	-2.32B
EPS	-5.99
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,050
Average Volume	108,393
Open	37.48
Previous Close	43.22
Day's Range	36.66 - 40.39
52-Week Range	22.25 - 55.18
Beta	1.34
RSI	49.03
Earnings Date	Feb 13, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 5,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A45

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD